SMS Terms

This site is intended for U.S. Healthcare Professionals.

Report Adverse Event
Report Adverse Event to VAERS
Report Adverse Event to Pfizer
Patient Vaccine Finder Order on Pfizer Prime
Order on Pfizer Prime

BioNTech & Pfizer COVID Connect SMS Text Messaging Program Terms & Conditions

  1. Joining the BioNTech & Pfizer COVID Connect SMS text messaging program is optional and is not required or a condition to make any purchase. By opting in to the BioNTech & Pfizer COVID Connect SMS text messaging program, you consent to receive up to 8 text messages per month from Pfizer Inc. Such messages may be marketing related and may include, for example, updates regarding Product Availability.
  2. To stop receiving text messages, text STOP to 21215. DOING SO WILL ONLY OPT YOU OUT OF THE BioNTech & Pfizer COVID Connect SMS text messaging program; you will remain opted in to any other Pfizer Inc. text message program(s) to which you separately opted in.
  3. To request more information or to obtain help, text HELP to 21215.
  4. You agree to Pfizer’s Privacy Policy, available at www.Pfizer.com/privacy, which is hereby incorporated as part of these terms.
  5. You represent that you are a US healthcare provider and the account holder for the mobile telephone number(s) that you provide to opt-in to the texting program. You are responsible for notifying Pfizer Inc. immediately if you change your mobile telephone number. You may notify Pfizer Inc. of a number change by calling 833-991-1933.
  6. Message and data rates may apply to each text message sent or received in connection with the texting program, as provided in your mobile telephone service rate plan (please contact your mobile telephone carrier for pricing plans), in addition to any applicable roaming charges. Charges are both billed and payable to your mobile service provider or deducted from your prepaid account. Pfizer Inc. does not impose a separate fee for sending text messages.
  7. Alerts sent via SMS may not be delivered if the mobile phone is not in range of a transmission site or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of the wireless carrier may interfere with message delivery, including the customer’s equipment, terrain, proximity to buildings, foliage, and weather. The wireless carrier does not guarantee that alerts will be delivered and will not be held liable for delayed or undelivered messages.
  8. For information on data collection and use, please read Pfizer Inc.’s full corporate Privacy Policy at www.Pfizer.com/privacy, which is incorporated by reference into these Terms.
  9. Pfizer Inc. will not be liable for any delays in the receipt of any SMS messages, as delivery is subject to effective transmission from your network operator.
  10. You agree to indemnify Pfizer Inc. and parties texting on its behalf in full for all claims, expenses, and damages related to or caused in whole or in part by your failure to notify Pfizer Inc. if you change your telephone number, including but not limited to all claims, expenses, and damages related to or arising under the Telephone Consumer Protection Act.
  11. The service may not be available through all mobile carriers.
  12. Pfizer Inc. may suspend or terminate your receipt of text messages if it believes you are in breach of these BioNTech & Pfizer COVID Connect SMS text messaging program Terms and Conditions. Your receipt of text messages is also subject to termination in the event that your mobile telephone service terminates or lapses. Pfizer Inc. reserves the right to modify or discontinue, temporarily or permanently, all or any part of the text messaging services you receive, with or without notice.
  13. Pfizer Inc. may revise, modify, or amend these BioNTech & Pfizer COVID Connect SMS text messaging program Terms and Conditions at any time. Any such revision, modification, or amendment shall take effect when it is posted to Pfizer Inc.’s website. You agree to review these BioNTech & Pfizer COVID Connect SMS text messaging program Terms and Conditions periodically to ensure that you are aware of any changes. Your continued consent to receive text messages will indicate your acceptance of those changes.

For more information

Pfizer Customer
Service

Including General Product Questions

Call 1-800-879-3477
Medical
Information
Visit PfizerMedicalInformation.com
Shipment Support
US Trade Customer Service
Call 1-800-666-7248

Pfizer Customer Service

Including General
Product Questions

Call 1-800-879-3477

Medical Information

Visit
PfizerMedicalInformation.com

Shipment Support US Trade Customer Service

Call 1-800-666-7248

Get COVID-19 Vaccine Text Updates Enroll in the BioNTech & Pfizer COVID Connect text messaging program for U.S. Healthcare Professionals.
Sign Up
Call a Pfizer Connect Representative Live representatives available 9 AM–5 PM ET to help HCPs answer product questions, discuss Pfizer Prime ordering, and more.
Call 1-844-966-5127

IMPORTANT SAFETY INFORMATION

Expand

Collapse

AUTHORIZED USE

IMPORTANT SAFETY INFORMATION

Expand

Collapse

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.

IMPORTANT SAFETY INFORMATION

Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of Pfizer-BioNTech COVID-19 Vaccine.

Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention (CDC) guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis

Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations
/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to Pfizer-BioNTech COVID-19 Vaccine.

Limitation of Vaccine Effectiveness

Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients.

Adverse Reactions

Solicited adverse reactions included:

  • 6 months through 23 months of age: Injection site redness; swelling and tenderness; decreased appetite; drowsiness; fever; irritability.
  • 2 through 11 years of age: Injection site pain; redness and swelling; chills; diarrhea; fatigue; fever; headache; new or worsened joint pain; new or worsened muscle pain; vomiting.

Vaccination providers must report all vaccine administration errors, all serious adverse events, cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS), and cases of COVID-19 that result in hospitalization or death following administration of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) to the Vaccine Adverse Event Reporting System (VAERS) by submitting online at https://vaers.hhs.gov/reportevent.html. Vaccination providers administering COMIRNATY (COVID-19 Vaccine, mRNA) (2024-2025 Formula) under EUA must adhere to the same reporting requirements. For further assistance with reporting to VAERS call 1-800-822-7967. The reports should include the words “Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) EUA” in the description section of the report. To the extent feasible, report adverse events to Pfizer 1-800-438-1985 or provide a copy of the VAERS form to Pfizer https://
www.pfizersafetyreporting.com/.

Please click for Pfizer-BioNTech COVID-19 Vaccine Vaccination Provider and
Recipient and Caregiver EUA Fact Sheets.

AUTHORIZED USE

Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months through 11 years of age.